Traditional and new biomarkers of congestion in heart failure

Česká verzia

Authors: Táňa Andreasová ¹; Filip Málek ^1,2
Authors place of work: Kardiovaskulární centrum, Nemocnice Na Homolce, Praha ¹; Interní klinika FNKV a 3. LF UK Praha ²
Published in the journal: Vnitř Lék 2022; 68(8): 514-516
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2022.109

Summary

The presence of pulmonary and systemic congestion is the main cause of the poor outcome of the patients with heart failure. Despite of the availability of several tools of the modern medicine, the degree of congestion is usualy difficult to evaulate. The clinical, imaging and laboratory methods are the tools, which can estimated the degree of congestion.

Keywords:

heart failure – biomarkers – congestion

Zdroje

1. Girerd N, Seronde MF, Coiro S et al. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Failure. 2018; 6(4):273-285.

2. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168:2186-94.

3. Maddox TM, Januzzi JL, Allen LA et al. 2021 Update to the 2017 ACC Expert Consensus Decision pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. JACC. 2021; 77(6):772-810.

4. Špinar J, Málek F, Špinarová L et al. Úprava guidelines ACC pro léčbu srdečního selhání v roce 2021. Cor Vasa. 2021;62:264-270

5. Gheorghiade M, Follath F, Ponikowski P et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive. Care Medicine. Eur J Heart Fail 2010;12:423-33.

6. Mentz RJ, Kjeldsen K, Rossi GP et al. Decongestion in acute heart failure. Eur J Heart Fail. 2014;16:471-82.

7. Beneš J, Kotrč M, Conrad MJ, et al. Exercise dynamics of cardiac biomarkers and hemoconcentration in patients with chronic systolic heart failure. J Card Fail. 2020,26(12):1100-1105.

8. Duarte K, Monnez JM, Albuisson E et al. Prognostic value of estimated plasma volume in heart failure. J Am Coll Cardiol. HF. 2015;3:886-93.

9. Pitt B, Remme W, Zannad F et al. For the Eplerenone Post‑Acute Myocardial. Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.

10. Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-96.

11. Brisco MA, Coca SG, Chen J et al. Blood urea nitrogen/creatinine ratio identifies a high‑risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ Heart Fail. 2013;6:233-9.

12. Shinagawa H, Inomata T, Koitabashi T et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J. 2008;72:364-9.

13. Felder L, Mund A, Parker JG. Liver Function Test in Chronic Congestive Heart Failure. Circulation 1950,2(2):286-297.

14. Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009;4: 2013-2026.

15. Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001;96:122-131.

16. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007;116:1549-1554.

17. Zile MR, Bennett TD, St. John Sutton M et al.Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008;118:1433-1441.

18. Núñez J, Miňana G, Nuňez E et al. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail Rev. 2014;19:575-584.

19. Fudim M, Felker M. Biomarkers of Congestion. Emerging Tools in the Management of Heart Failure? JACC Heart Failure. 2020,8(5):398-400.

20. Núñez J, Nunez E, Sanchis J et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol. 2012;159:21-8.

21. Núñez J, Llacer P, Bertomeu‑Gonzalez V et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE‑HF: a randomized study. J Am Coll Cardiol HF. 2016;4:833-43.

22. Núñez J, Llacer P, Garcia‑Blas S et al. CA125- Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. Am J Med. 2020;133:370–80.e4.

23. Núñez J, Bayés‑Genís A, Revuelta‑López E et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT‑CHF study subanalysis. J Am Coll Cardiol HF. 2020;8:386-97.

24. Arrigo M, Truong QA, Onat D et al. Soluble CD146 is a novel marker of systemic congestion in heart failure patients: an experimental mechanistic and transcardiac clinical study. Clin Chem. 2017;63:386-393.

25. Gayat E, Caillard A, Laribi S. et al. Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. Int J Cardiol 2015;199:241-247.

26. Kubena P, Arrigo M, Parenica J et al. Plasma levels of soluble CD146 reflect the severity of pulmonary congestion better than brain natriuretic peptide in acute coronary syndrome. Ann Lab Med. 2016;36:300-305.

27. Peacock WF. Novel biomarkers in acute heart failure: MR‑pro‑adrenomedullin. Clin Chem Lab Med. 2014;52:1433-1435.

28. Maisel A, Mueller C, Nowak RM et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2011;58:1057-1067

29. Willenbrock R, Langenickel T, Knecht M, et al. Regulation of cardiac adrenomedullin‑mRNA in different stages of experimental heart failure. Life Sci. 1999;65:2241-2249.

30. Fudim M, Lerman JB, Page C et al. Plasma Volume Status and Its Association With In‑Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure. 2021;27(3):297-308.

31. Tamaki S, Yamada T, Morita T et al. Comparison of the prognostic values of formulas for the estimation of plasma volume in patients admitted for acute decompensated heart failure: a prospective study. Eur Heart J Suppl. 2018, ehy565.P2820